{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=9",
    "query": {
      "condition": "Neuroectodermal Tumor",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 5013,
    "total_pages": 502,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroectodermal+Tumor&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T19:34:00.238Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00746746",
      "title": "A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "HyperAcute vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegylated Interferon-Alpha 2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Ochsner Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-06",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2011-01-13",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00746746"
    },
    {
      "nct_id": "NCT04417088",
      "title": "Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Exablate BBBD",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "InSightec",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 28,
      "start_date": "2020-11-06",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-20",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Baltimore, Maryland • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04417088"
    },
    {
      "nct_id": "NCT04007588",
      "title": "A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma Stage III",
        "Melanoma Stage IV"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "BMS-986205",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-09-06",
      "completion_date": "2019-12-19",
      "has_results": false,
      "last_update_posted_date": "2020-02-05",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04007588"
    },
    {
      "nct_id": "NCT06322342",
      "title": "Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System (CNS) Lesions",
        "Brain Metastases",
        "Brain Neoplasms",
        "Brain Neoplasms, Benign",
        "Brain Tumor, Primary",
        "Brain Tumor, Recurrent",
        "Brain Tumors",
        "Brain Cancer",
        "Brain Tumor",
        "Brain Neoplasm, Primary",
        "Multiple Sclerosis",
        "Multiple Sclerosis Brain Lesion",
        "Neurofibroma",
        "Acoustic Neuroma",
        "CNS Tumor",
        "CNS Lesion",
        "CNS Metastases",
        "CNS Cancer",
        "CNS Lymphoma",
        "Von Hippel Lindau",
        "Meningioma",
        "Glioma",
        "Schwannomas",
        "Neuroinflammation",
        "Neoplasia"
      ],
      "interventions": [
        {
          "name": "RVP-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reveal Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2024-08-15",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2025-12-26",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Columbia, Missouri + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06322342"
    },
    {
      "nct_id": "NCT04614766",
      "title": "A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastro-enteropancreatic Neuroendocrine Tumor",
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Lutathera",
          "type": "DRUG"
        },
        {
          "name": "Azedra",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David Bushnell",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-09-30",
      "completion_date": "2024-04-23",
      "has_results": false,
      "last_update_posted_date": "2024-04-29",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04614766"
    },
    {
      "nct_id": "NCT00646022",
      "title": "Natural History of Familial Carcinoid Tumor",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Carcinoid"
      ],
      "interventions": [
        {
          "name": "[18F]-DOPA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 1600,
      "start_date": "2008-08-25",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00646022"
    },
    {
      "nct_id": "NCT00005617",
      "title": "Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "dendritic cell-MART-1 peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "leukapheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1997-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-08-03",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005617"
    },
    {
      "nct_id": "NCT03072160",
      "title": "Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Medullary Thyroid Cancer (MTC)"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2017-06-16",
      "completion_date": "2019-11-22",
      "has_results": true,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03072160"
    },
    {
      "nct_id": "NCT02385669",
      "title": "A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "6MHP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Craig L Slingluff, Jr",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2015-04",
      "completion_date": "2019-09-18",
      "has_results": true,
      "last_update_posted_date": "2020-05-05",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02385669"
    },
    {
      "nct_id": "NCT05026983",
      "title": "Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Metastatic Melanoma",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Encorafenib",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2021-12-27",
      "completion_date": "2027-02-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-10-23T19:34:00.238Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05026983"
    }
  ]
}